CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of a Phase 2 trial of defactinib (VS-6063), a potent inhibitor of focal adhesion kinase (FAK), in KRAS-mutated non-small cell lung cancer (NSCLC).
Help employers find you! Check out all the jobs and post your resume.